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Coronavirus Disease-19: Vaccine Production and 
Development
S. Jatin Singh*
Ab s t r Ac t
The coronavirus disease (COVID-19) pandemic, which emerged in Wuhan, China, in late December 2019, is now rampantly spreading 
worldwide. There is a serious need for ultimate treatment of the disease, to stop the spread of the virus globally. In these unprecedented 
times, vaccines can play a pivotal role in strengthening the immunity of the community. Many drugs are being prescribed in hospital 
setups to treat the disease caused by the virus. Most of these drugs act as tools for symptomatic relief and palliative care in individuals. 
A noteworthy drug, favipiravir is being used in some countries like India, for COVID-19 positive patients, who have been hospitalized, in 
a debilitated state. However, drugs provide a cure at an individual level, but to control such a massive pandemic, a safe and efficacious 
vaccine is needed. Vaccines are the tools that have a huge impact on “herd immunity.” Not only the researchers but also the general public 
are eagerly anticipating the development of the vaccine so that they can be relieved of the multiple lockdowns and can rest assured. Unless 
a safe and efficacious vaccine against SARS-CoV-2 is developed, there is always a risk of new outbreaks of the disease. This article highlights 
some important points that help us feed the curiosities, with information on, what is a vaccine? Why do we need a vaccine for COVID-19? 
How will the vaccine develop?
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In t r o d u c t I o n
Many people across the globe are suffering from this devastating 
disease that has either disturbed the life of people or taken lives. 
A proper solution to combat this disease is by vaccination, and 
that is why nearly 150 countries have taken up the challenge of 
developing a vaccine and nearly 200 prophylactic vaccines are 
currently in development against coronavirus disease (COVID-19), 
at an accelerated pace.[1,2]
To produce an effective vaccine, it is important to know the 
structure of the virus.
COVID-19 is caused and spread by an infectious virus, SARS-
CoV-2 that belongs to the family of Coronaviridae. Coronaviridae is 
a family of enveloped, positive-sense single-stranded RNA viruses 
that carry petal or club-shaped peplomers (Spikes).[3]
Like alternative coronaviruses, SARS-CoV-2 particles are spherical 
in shape and have proteins known as “spikes” jutting from their 
surface. A new modality like cryoelectron microscopy is done to take 
detailed pictures of the structure of the spike protein (S-protein).[4]
The spikes latch onto the ACE-2 receptor on human cells then, 
they undergo structural modification that enables the infectious 
agent membrane to fuse with the plasma membrane, and this is 
known as membrane fusion. Before entering the host cell, the virus 
particle is uncoated and the Ribonucleic acid is deposited into the 
cytoplasm.
Some researchers found that the SARS-CoV-2 spike has 10–20 
times more affinity to bind ACE2 receptors on human cells than the 
SARS -2002 virus spikes. This makes SARS-Cov-2 more infectious 
than the earlier virus.[3,4]
The virus has many serotypes that are very fastidious which makes 
it a difficult process to grow in cell cultures. Most human coronaviruses 
come under either of the serotypes: OC43-like, 229E-like; other 
serotypes are SARS-CoV, NL63, HKU-1, and MERS-CoV.[4]
The researchers are currently engaged in developing vaccine 
candidates that target the SARS-CoV-2 S-protein. They additionally 
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hope to use the spike protein to isolate antibodies from those 
who have recovered from the infection. If created in massive 
quantities; such antibodies might probably be useful in treating 
new infections before a vaccine is obtained.[5]
Wh At I s A VAcc I n e?
A vaccine is a biological preparation that is used to stimulate the 
production of antibodies and provide immunity against one or 
many diseases. It provides artificially acquired active immunity to 
a particular infectious disease.
It is usually made from weakened or killed forms of the 
microbe, its toxins, or one of its surface proteins.[3]
In the case of SARS-CoV-2, there is more research going on the 
S-Protein that could act as a potential antigen to create antibodies 
against the virus.
Why do We ne e d A VAcc I n e f o r 
coVId-19?
The main process by which anyone can fight the disease is by 
strengthening one’s immunity against the disease. This can be 
achieved in two ways, either by getting infected and developing 
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antibodies (natural immunity) or by vaccination (artificial 
immunity).
The immune system of our body is capable of protecting us 
from invading pathogens by producing immunoglobulins. If the 
immune system is not fast enough, the pathogens invade and 
we fall sick. Vaccines mimic the actual pathogen and provide a 
balanced and controlled exposure of pathogens.
It is more important for the whole community to acquire 
immunity and that can be achieved by herd immunity.
Herd immunity is the overall level of immunity in a 
community/population. When an outsized proportion of people in 
a community are immune to a microorganism, the herd immunity 
to the microorganism is considered satisfactory. Eradication of 
communicable diseases depends on the development of high 
levels of herd immunity.[3]
Herd immunity concept is used in the production of vaccines 
that have successfully controlled deadly contagious diseases such 
as smallpox, polio, diphtheria, and rubella.[5]
Often, a proportion of the population should be capable 
of obtaining a disease so as for it to spread. This is known as a 
threshold proportion. If the proportion of the population that 
is immune against the disease is more than this threshold, the 
spread of the disease can decline. This is called the herd immunity 
threshold.[6]
The herd immunity threshold of SARS-Cov-2 is 29–80%, on an 
average 60%, that is, at least 60% of people in a community should 
be vaccinated to stop the spread.[7]
Some health-care professionals contradict the idea that 
attaining herd immunity through natural exposure to the 
pathogen. “This pandemic cannot be overcome by thinking that 
tomorrow we will have herd immunity. Herd immunity has failed 
in the UK. There is no point in saying that India has developed 
herd immunity. We have tried to contain the virus through the 
lockdown” as said by a professor at All India Institute of Medical 
Sciences.[8]
hoW A r e coVId-19 VAcc I n e s Pr o d u c e d?
An ideal SARS vaccine should have three features as follows:
1. It should be able to elicit highly potent neutralizing antibodies 
against a broad spectrum of viral strains
2. Induce protection against infection and transmission
3. Should be safe by not inducing any infection-enhancing 
antibodies or harmful immune or inflammatory responses.[9]
All the vaccines have to undergo a series of clinical trials that 
include the phases shown in Table 1.[10]
To respond faster to the COVID-19 pandemic, a broad range of 
candidate COVID-19 vaccines are being investigated using various 
technologies and platforms including viral-vectored, protein 
subunit, nucleic acid (deoxyribonucleic acid [DNA], and RNA), live 
attenuated, and inactivated vaccines, of which some have entered 
clinical trials.[11]
Before we deal with the vaccines against COVID-19, it is 
essential to know, what the types of vaccines are.
Live Attenuated Vaccines
Live attenuated vaccines contain live microbes that are rendered 
avirulent. Live vaccines induce a wide range of antibodies to many 
viral antigens. This vaccine tends to be more effective, provides 
immunity that lasts longer than the killed ones. One dose is usually 
sufficient. However, they pose a risk of reversion to virulence, but 
this is a rare drawback. These vaccines should be used cautiously 
or are contraindicated in immune-suppressed individuals
Inactivated/Killed Vaccines
It consists of microbes killed by heat or chemicals. They require 
a series of injections before prior immunization. The immunity 
is comparatively short-lasting and might require multiple doses. 
Subunit vaccines pose less adverse reactions, as the virus is split 
by detergents and other chemicals, and only required antigens are 
incorporated in the vaccine.
These vaccines induce cell-mediated immunity.[3,10]
Many pharmaceutical company firms are pioneering in using 
innovative technologies in producing effective vaccines.
AstraZeneca’s AZD-1222 and Moderna’s mRNA-1273 are 
presently the foremost promising vaccine candidates, each using 
novel technologies that include delivering and manufacturing 
the COVID-19 (S-protein) into the body to mount a reaction. This 
mechanism is anticipated to supply a long-lasting immunity by 
altering the binding of the S-proteins of the coronavirus to stop 
the infection.[2]
Moderna’s - mRNA-1273 vaccine candidate inserts a 
messenger ribonucleic acid (mRNA) sequence into the body that 
encodes for the S-protein, leading to the production of the 2019-
nCoV S-protein, which induces the host cells to mount an immune 
response against the S-protein. This vaccine is expected to enter 
the phase-3 trial by July 27, 2020.[2]
While Moderna was working on mRNA based vaccine, 
AstraZeneca collaborated with the University of Oxford in the 
development of a recombinant adenoviral vaccine, AZD-1222.
AZD-1222 uses genetically altered adenovirus to prevent 
replication and consists of a replication-deficient chimpanzee 
adenovirus vector (ChAdOx1), which delivers the S-protein. 
Moreover, the Oxford University claims that the vaccine under 
development can provide “double protection” by inducing 
antibody production as well as the Killer-T-lymphocytes that kill 
the virus-infected cells.[2,12]
CureVac is another mRNA based vaccine that is currently in 
phase-1 of the clinical trial.
Sinovac Biotech is developing CoronaVaC, an inactivated 
vaccine that is currently in Phase I/II trial. The preliminary results 
have shown the vaccine to exhibit a favorable safety profile.[2,13]
Table 1: Various phases a vaccine goes through
Preclinical studies Phase-1 Phase-2 Phase-3 FDA review Phase-4
Exploratory studies of 
synthesized vaccine
Human pharmacology 
safety and dosing of 
vaccine
Therapeutic 
exploration and 
effectiveness
Therapeutic 
confirmation and 
comparison 
To confirm the safety 
and effectiveness of 
the drug
Post marketing 
surveillance/Data 
gathering studies
Tested on animals 
to explore the 
pharmacological profile
Total 20–80 human 
subjects
100–500 human 
subjects
500–3000 human 
subjects
1000+ human 
subjects
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Inovio INO-4800 utilizes innovative DNA immunogen 
technology composed of changed plasmids to supply associate 
degree response targeting the S-protein. Inovio had declared that 
the preliminary clinical test results showed INO-4800 to be safe 
and tolerable.[2]
Covaxin is India’s 1st candidate against SARS-CoV-2 infection. 
Covaxin is an inactivated vaccine. The vaccine has been developed 
by a pharmaceutical company, Bharat Biotech in collaboration 
with the National Institute of Virology and Indian Council of 
Medical Research (ICMR). The Drug Controller General of India 
(DCGI) earlier approved the biotech company to initiate Phases I 
and II human clinical trials.
As the number of cases are exploding across the planet, 
vaccines are being developed at an accelerated pace. ICMR has 
once again said that there is nothing wrong with the ambitious 
vaccine timeline and even went on to say that India will have a “big 
role” to play in vaccine development globally.[12]
Various pharmaceutical companies and biotech firms are 
developing intramuscular vaccines that are under different 
phases of clinical trials while some firms in different countries are 
developing a nasal/mucosal route of administration of vaccines.
Intranasal vaccines are sprayed through nose/orally to the 
respiratory tract. It target he nearby B-lymphocytes that produce 
immunoglobulin-A that provides local immunity and helps in 
healing the mucosal surface and also the B-lymphocytes induce 
the T-lymphocytes that provide systemic immunity. A mucosal 
vaccination is beneficial as it triggers local, as well as systemic 
immunity whereas intramuscular vaccination mainly induces an 
antibody response.
 Moreover, the nasal spray particles are aerosolized and can get 
lodged in the lungs, intestines, and hence provide immunity.[12,13]
At present, many firms of different countries are developing 
various intranasal vaccines, some of them are:
Coroflu
The vaccine development firm, FluGen has collaborated with the 
University of Wisconsin-Madison to produce the vaccine called 
Coroflu. Coroflu is developed on the basis of the M2SR flu vaccine, 
which is a self-limiting version of the influenza virus that induces 
an immune response against the flu.[13,14]
Canadian Vaccine
This vaccine candidate is a DNA-based vaccine that can be given 
through a nasal route. The University of Waterloo in Canada is 
developing the vaccine. The scientists are using a novel approach 
based on bacteriophages.[13]
Intravacc
This is a Dutch research and development vaccine institute 
established in the Netherlands. Intravacc has collaborated with 
Wageningen Bioveterinary Research and Utrecht University to 
develop an intranasal Covid-19 vaccine. The vaccine will contain 
a Newcastle disease virus, that acts as a vector, which expresses 
the SARS-CoV-2’s immunogenic spike (S) protein, the main target 
for neutralizing antibodies, it demonstrated safety for intranasal or 
intratracheal delivery in mammals.[13,15]. Other intranasal vaccines 
AdCOVID and Finland nasal spray are still in preclinical trials.[13] The 
time at which the vaccines will be available is highly variable. Many 
scientists and researchers are slogging harder and working faster 
to create viable protection for mankind against COVID-19.
co n c lu s I o n
COVID-19 is a highly infectious disease caused by SARS-CoV-2. The 
disease has become a pandemic, that caused a huge economical 
imbalance due to restrictions in trade and lockdowns in the market. 
Across the globe, people are living a “socially-compromised life” 
like staying at homes, restricted movement due to the quarantine 
of contacts and isolation of cases. Many individuals are looking 
forward to the work of many pharmaceutical companies and 
vaccine development firms. These companies have invested 
billions of dollars in vaccine development.  Multiple clinical trials 
are being conducted in various countries to produce a vaccine. 
But, until then individuals should follow all the guidelines given by 
the governing bodies in order to stop the spread of the infection. 
The responsibility to reduce the infection lies in the hands of both 
community and the healthcare professionals. Hence, the citizens 
of the community and the healthcare system should be united in 
order to live a healthy life.     
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